Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Hanmi Halts Olmutinib Development After Alliances Crumble

Apr 17 2018

• By Jung Won Shin

Hanmi Pharmaceutical — HANMI CULLS OLMUTINIB

Related Content

Tagrisso Reimbursed In Korea, After Difficult Price Negotiations

Dec 14 2017

Korean Pharmas To Highlight Lung Cancer Pipeline Progress At AACR

Apr 12 2018

Surprise Boehringer Decision Turns Hanmi Investors’ Hopes To Despair

Sep 30 2016

Hanmi Toughens Controls As Employees Arrested For Insider Trading

Dec 15 2016

Poziotinib Shows Promise In EGFR Exon 20 Mutant NSCLC

Oct 19 2017

Rolontis Leads Hanmi’s Global Ambitions As ADVANCE Phase III Endpoint Met

Feb 09 2018

Hanmi Mulls New Trial Strategy As ZAI Lab Ends Olmutinib Partnership

Apr 03 2018

Korea To Limit Olmutinib Usage, Monitor All Patients

Oct 05 2016

Related Companies

Hanmi Pharmaceutical Co., Ltd.

Zai Lab Ltd.

Boehringer Ingelheim GmbH

Spectrum Pharmaceuticals, Inc.

Luye Pharma Group, Ltd.

Additional Topics

South Korea Asia Pacific Research & Development Clinical Trials Cancer BioPharmaceutical

More from R&D

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window